Relief Therapeutics Holding SA (OTCPK:RLFTF) Stock News, Headlines & Updates
Relief Therapeutics Holding SA Stock News from GuruFocus
- 1
- 2
Mar 27, 2024
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
ACCESSWIRE • 3:00am
Mar 22, 2024
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
ACCESSWIRE • 3:00am
Feb 28, 2024
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
ACCESSWIRE • 3:00am
Dec 05, 2023
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
ACCESSWIRE • 3:00am
Nov 22, 2023
Relief Therapeutics Announces CEO Transition
ACCESSWIRE • 3:00am
Oct 10, 2023
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
ACCESSWIRE • 3:00am
Sep 01, 2023
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
ACCESSWIRE • 3:00am
Jul 19, 2023
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
ACCESSWIRE • 3:00am
Feb 02, 2022
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
ACCESSWIRE • 3:00am
Jul 26, 2021
Relief Therapeutics Announces CHF 15 Million Private Placement
ACCESSWIRE • 3:00am
Jul 23, 2021
Relief Reports that its U.S. Collaboration Partner has Announced Successful Commercial Formulation for Aviptadil
ACCESSWIRE • 3:00am
Jul 22, 2021
Relief Announces Issuance of Shares from Authorized Capital as Approved by 2021 Annual General Meeting
ACCESSWIRE • 3:00am
Jul 20, 2021
Relief Reports that its U.S. Collaboration Partner has Presented Evidence that Aviptadil Helps to Prevent Cytokine Storm in Patients with COVID-19
ACCESSWIRE • 3:00am
Jul 13, 2021
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, and Quantum Leap Announce Treatment of Severely Ill COVID-19 Patients with Aviptadil in the I-SPY COVID Trial
ACCESSWIRE • 3:00am
Jun 29, 2021
Relief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APR
ACCESSWIRE • 3:00am
Jun 21, 2021
Relief Announces the Results of the Annual General Meeting 2021 of RELIEF THERAPEUTICS Holding AG: All Proposals Approved by a Large Majority
ACCESSWIRE • 3:00am
Jun 16, 2021
Relief Therapeutics Reports that Collaboration Partner, NRx Pharmaceuticals, has Announced Additional Results from the Aviptadil U.S. Expanded Access Protocol for Patients with Critical COVID-19
ACCESSWIRE • 3:00am
Jun 02, 2021
Relief Therapeutics Reports that its Collaboration Partner, NRx Pharmaceuticals, has Submitted an Application for Emergency Use Authorization for Aviptadil to the U.S. Food & Drug Administration
ACCESSWIRE • 3:00am
May 28, 2021
Relief Appoints Dr. Taneli Jouhikainen as Chief Operating Officer
ACCESSWIRE • 3:00am
May 27, 2021
Relief Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding AG
ACCESSWIRE • 3:00am
May 18, 2021
Relief Provides Update on Progress and Plans with ACER-001 for the Treatment of Urea Cycle Disorders
ACCESSWIRE • 3:00am
May 17, 2021
Relief Points to Applied Pharma Research (APR) News re: Pivotal COVID-19 Trial Initiation with Novel Nasal Spray
ACCESSWIRE • 3:00am
May 04, 2021
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
ACCESSWIRE • 3:00am
Apr 19, 2021
Relief Comments on Certain Statements Made by NeuroRx, Inc. in the Amended Form S-4 Filing of Big Rock Partners Acquisition Corp.
ACCESSWIRE • 4:00am
Mar 08, 2021
Relief Increases Issued Share Capital with Creation of Treasury Shares
ACCESSWIRE • 2:59am
Feb 24, 2021
NeuroRx Announced that RLF-100(TM) has Demonstrated Ten-Day Accelerated Recovery from Respiratory Failure among Patients with Severe Covid-19 Treated with HFNO at 28 Day Interim Endpoint
ACCESSWIRE • 2:59am
Feb 09, 2021
Relief Announces Resignation of Thomaz Burckhardt as Member of the Board of Directors
ACCESSWIRE • 2:59am
Relief Affirms Initiation of Phase 2/3 Trial of Inhaled RLF-100(TM) (Aviptadil; ZYESAMI(TM)) in Severe COVID-19 Patients
ACCESSWIRE • 6:59pm
Jan 25, 2021
Dec 18, 2020
Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority
ACCESSWIRE • 11:00am
Dec 07, 2020
NeuroRx and Relief Therapeutics Meet 165 Patient Enrollment Target in Phase 2b/3 Trial of RLF-100â„¢ for Critical COVID-19 with Respiratory Failure
PRNewswire • 3:00am
Nov 25, 2020
Nov 24, 2020
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100â„¢ (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
PRNewswire • 11:02am
Nov 13, 2020
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100â„¢ for Critical COVID-19 with Respiratory Failure
PRNewswire • 7:01am
Nov 05, 2020
NeuroRx and Relief Therapeutics announce continuation of RLF-100â„¢ trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
PRNewswire • 7:04am
Nov 04, 2020
Relief Appoints J. Paul Waymack, M.D., Sc.D. as Consultant to Strengthen Management Team
ACCESSWIRE • 3:00am
Oct 13, 2020
Oct 08, 2020
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
ACCESSWIRE • 3:00am
Sep 30, 2020
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100â„¢ (aviptadil)
PRNewswire • 3:00am
Sep 28, 2020
- 1
- 2
Show
Entries
Headlines
Total 0- 1
No recent news
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers